Press Releases
ThinkEquity LLC hosts a panel discussion on ovarian cancer treatments
San Francisco, February 14, 2006 — ThinkEquity LLC, a research-centric investment bank, announced today that it will host a forum led by members of its healthcare equity research team and industry experts to examine current ovarian cancer treatments.
The forum includes a distinguished team of doctors who will address current ovarian cancer treatments such as Doxil, Hycamptin and the platinums and experimental therapeutics in the clinic including TOCOSOL paclitaxel, Avastin and Telcyta. They will also speak about the current and future market opportunity for these therapies. Panel members include:
- Dr. Allan Covens
Gynecologic Oncology Site Group Leader, Toronto Sunnybrook Cancer Centre - Dr. Maurie Markman
VP of Clinical Research, MD Anderson Cancer Center, Houston, TX - Dr. William McGuire
University of Maryland, Franklin Square Hospital Center, Baltimore, MD
WHEN:
Friday, May 5, 2006
11:30 AM - 1:30 PM
WHERE:
The Ritz-Carlton New York, Central Park
More information about the event can be found at www.thinkequity.com »
About ThinkEquity
ThinkEquity is a research-centric institutional investment firm focused on the growth economy. ThinkEquity merger with Panmure Gordon in March 2007 provides its clients with global investment banking services. The firm is dedicated to providing focused insight, advisory services, and capital to institutional investors and corporate constituents in the knowledge economy's key growth verticals, including technology, healthcare, media/education and consumer/business services. For more information about ThinkEquity, please visit www.thinkequity.com. Member FINRA and SIPC.
For more information please contact:
Peter Coleman
Chief Operating Officer
ThinkEquity
415-249-2900
or
Jennifer Jones
650-529-1416
jennifer@jenniferjones.com